At this year’s BIO International Convention 2025, pharmaphorum’s Jonah Comstock sat down with Paul Romness, CEO of OS Therapies, and Farah Ahmad, VP of Business Development at EVERSANA, to explore how emerging biotech companies are navigating today’s volatile landscape—and why global collaboration is more critical than ever.
In the interview, Romness shared OS Therapies’ mission to bring hope to children battling osteosarcoma through OST-HER2, a novel therapy now approaching FDA review. He emphasized the emotional and scientific stakes of pediatric oncology, noting that the company’s advocacy roots are deeply personal and purpose driven.
Ahmad highlighted how EVERSANA’s COMPLETE Commercialization® model is uniquely positioned to support companies like OS Therapies. From regulatory strategy to market access and commercialization, EVERSANA offers an integrated approach that allows emerging biotechs to stay nimble while scaling effectively and in a capital-efficient manner. “We’re built to meet companies where they are,” she said, “and help them go further, faster.” EVERSANA’s model cuts infrastructure and SG&A costs while boosting product performance, helping companies retain asset value and avoid costly out-licensing.
The conversation was a powerful reminder that in times of disruption, unity and partnership are not just strategic—they’re essential.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…